A Phase 1/2 Study of Chemo-Immunotherapy with Durvalumab and Pegylated Liposomal Doxorubicin (PLD) in Platinum-Resistant Recurrent Ovarian Cancer
Durvalumab/PLD combination shows promising efficacy and a tolerable safety profile in women with platinum-resistant ovarian cancer.
Early intervention and supportive care for gastrointestinal and hepatic toxicities should be considered for patients receiving PARP inhibitors.
Clinical Characteristics of Ovarian Cancer Relapse in BRCA1/2 Germ-Line Mutation Carriers and Noncarriers
Analysis of high-grade serous ovarian cancers suggests that BRCA1/2-driven cancers have a more favorable mode of relapse than sporadic cancers.
Results suggest that the combination of durvalumab and olaparib was well-tolerated and had clinical activity in heavily pretreated, BRCA-wildtype ovarian cancer patients.
Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and Stable Disease
Olaparib maintenance may prolong progression-free survival in patients, regardless of the number of previous platinum-based chemotherapies.
Long-Term Tolerability of Olaparib Tablets as Maintenance Therapy for Platinum-Sensitive Relapsed Ovarian Cancer
Similar to the capsule formulation, olaparib tablets have no cumulative toxicity, few late-onset adverse events, and a low rate of treatment discontinuation.
Effect of Prior Chemotherapy Regimens on Rucaparib Treatment in Platinum-Sensitive Recurrent Ovarian Carcinoma
Progression-free survival associated with rucaparib is not affected by the number of prior chemotherapy regimens.
Phase 3 Trial of Lurbinectedin vs Pegylated Liposomal Doxorubicin or Topotecan in Platinum-Resistant Ovarian Cancer Patients
Promising safety results from the CORAIL trial suggest a place for lurbinectedin in treating platinum-resistant ovarian cancer.
Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab vs Carboplatin/Gemcitabine/Bevacizumab in Patients with Recurrent Ovarian Cancer
The novel combination of carboplatin, pegylated liposomal doxorubicin, and bevacizumab has a promising safety and efficacy profile.
Patients receiving psychological support in the OVPSYCH2 randomized study showed reduced fear of progression compared with those without support.
Page 2 of 18
Results 11 - 20 of 179
Results 11 - 20 of 179